StockWatch
·

DEEPAK NITRITE LTD.-$ Q2 FY27 Results

DEEPAKNTRQ2 FY27 Results
Filing
Result:Very Good· Market: Up#Broad based#Margin expansion

Outlook: Optimistic · Guidance: Maintained

MetricValue (₹ Cr)Q1 FY27Q2 FY26
Revenue3.1K19.4%61.8%
Total Income3.1K19.3%60.9%
Expenditure2.5K20.1%45.0%
PBT542.7016.1%232.9%
Net Profit397.6815.3%234.9%
OPM20.38%0.58pp9.64pp
NPM12.86%0.45pp6.68pp
EPS29.1615.3%234.8%
View full financials

Chemicals sector beat: revenue up 61.8% YoY with OPM expanding ~960bps to 20.4% and PAT more than tripling, driven by core business strength rather than one-offs.

DEEPAK NITRITE · Q2 FY27 · THE VERDICT

Record PAT Masks the Real Story: AI Segment in Retreat

Deepak Nitrite posted record ₹398 Cr PAT (+235% YoY), but 80% of consolidated EBIT came from phenolics at cycle peak. The Advanced Intermediates segment—the growth engine—saw EBIT fall 27% quarter-on-quarter; new asset ramps are absorbing slower than guided. Polycarbonate entry pushed to FY31; the stock is down 52% from its all-time high.

04 Nov 2026 · 6 min read
Reported PAT

₹398 Cr

+235% YoY

Phenol EBIT

₹515 Cr

22% margin, +23% QoQ

AI EBIT

₹49 Cr

6% margin, -27% QoQ

The quarter in one sentence

Deepak Nitrite delivered record quarterly profit, but 80% of consolidated EBIT came from phenolics at commodity cycle peak. The Advanced Intermediates segment—the company's platform for long-term value creation—saw profitability collapse 27% quarter-on-quarter, signalling that new asset ramps are running slower than guided. The stock, down 52% from its all-time high, is pricing in skepticism that management can execute the recovery.

Where the profit came from

Phenolics drove Q2, posting ₹2,291 Cr revenue (highest ever, +72% YoY) and ₹515 Cr EBIT (22% margin). This segment is riding three tailwinds: a globally tight propylene market (pushing import costs higher, favoring Indian producers), domestic demand resilience (laminates, chemicals, autos stable at 6–7% annual growth), and Deepak's 4 lakh tonne capacity sustained on a debottlenecked basis. But management is candid: 'not a super cycle'—the market is at peak, driven by geopolitical supply disruptions, not structural demand.

Here is the tension. Advanced Intermediates, the growth segment Deepak is building via MIBK, MIBC, acetophenone, nitration, fluorination, and hydrogenation plants, posted only ₹49 Cr EBIT in Q2 (6% margin)—down 27% from Q1's ₹67 Cr. Revenue rose 38% YoY but stayed flat quarter-on-quarter at ₹811 Cr, entirely masked by phenolics dominance in the headline. These new assets, commissioned on schedule, are running at 60% utilization (MIBK/MIBC) and just launched (acetophenone ramping Q3). Market absorption is slower than historical cycles would suggest. This is not a supply problem; it is a demand-ramp issue.

Q2 FY27 EBIT by segment, ₹ Cr
0240.05480.11720.16515Phenol49Advanced Intermediates643Total
Phenolics accounts for 80% of consolidated EBIT. AI segment contribution still ramping.
Management's claims vs. what holds up

Achieved highest ever quarterly revenue and EBITDA

Q2 revenue ₹3,091 Cr (best-ever Q2), consolidated EBITDA ₹643 Cr (+187% YoY)

Supported

Phenolics highest ever quarterly revenue

Phenol segment ₹2,291 Cr (+72% YoY, +29% QoQ), confirmed as record

Supported

MIBK/MIBC/acetophenone operational by Q2

Both commissioned Q2; MIBK/MIBC at 60% utilization, acetophenone ramping Q3 onwards

Supported, but underutilized

H2 FY27 AI margin recovery expected toward Q1 levels (11%)

Management guided Q3 EBIT % 'between Q1 and Q2, closer to Q1'

Supported (guidance maintained)

What changed on this call

Three strategic shifts from the Q1 FY27 call:

  • Polycarbonate entry pushed from FY28–29 to FY31—a 2-year delay. Management now frames this as a pilot (running in Germany) moving to commercial scale in FY31, with interim resin imports bridging the gap.

  • Capex profile re-phased: less in FY27 (₹800–900 Cr H2 vs ₹3.2 Cr initially guided), more in FY28–30. Total ₹11.7 Cr remains unchanged; just deferred. Equity funding ~done; debt is the main lever.

  • Phenol cycle reassessment: no longer 'structural growth' but explicitly 'at peak' driven by geopolitical supply disruptions and freight tightness. If normalized, margin compression of 5–10 percentage points probable.

  • AI margin recovery timeline extended: new assets phased ramp over FY27–28 (not immediate). Target remains 14–15% EBIT margin by FY28–29, but absolute EBIT ₹240–400 Cr is contingent on 100%+ utilization (currently 60%).

The bull-bear ledger

Bull case
  • Record Q2 delivery on phenolics (₹2,291 Cr revenue, 22% EBIT margin) backed by structural domestic demand (laminates, chemicals, autos growing 6–7% annually)

  • New asset suite (chlorination, nitration, fluorination, hydrogenation) operational; REACH registration unlocks EU export for MIBK/MIBC

  • Polycarbonate platform (FY31 entry) de-risks commodity cyclicality; integrated phenol-to-polycarbonate supply is a structural moat

  • Net debt improved to ₹1,657 Cr (net D/E 0.25x); working capital cycle at 53 days showing operational discipline

Bear case
  • Phenol cycle at peak; normalization of geopolitical disruptions will compress margins 5–10 percentage points. Propylene supply tightness constrains ramp above 4 lakh tonne

  • AI segment EBIT fell 27% QoQ despite revenue +38% YoY—profitability deteriorating, not ramping as guided. 60% utilization suggests slower market absorption

  • Polycarbonate timeline slipped FY29→FY31; 18-month execution window is aggressive. Design, permitting, and customer qualification delay risk material

  • Reported PAT growth is price-driven, not volume-driven (management: 'volume roughly flat YoY'). Organic growth dependent on commodity cycle, not structural expansion

Risks, ranked by how much they should concern a holder

Phenol cycle peak → margin compression

High

Phenol EBIT margin at 22% reflects geopolitical tailwinds (freight, import tightness, propylene supply disruptions). Management candid: 'not a super cycle.' Normalization will compress margins 5–10pp, cutting PAT ₹50–100 Cr+ per percentage point. Propylene feedstock tightness also constrains ramp above 4 lakh tonne.

AI margin recovery timing uncertain

High

Q2 AI EBIT fell 27% QoQ; target 14–15% margin not imminent. Management guided Q3 'closer to Q1' (11%), but new assets running at 60% utilization. If market absorption slower than expected, recovery could slip into FY28 or beyond, compressing ROE on ₹700 Cr+ H1 capex.

Polycarbonate execution risk & 2-year delay

High

FY31 entry is 18 months away; requires PDH plant ramp, resin pilot qualification at scale, and customer approvals across 500+ grades. Any slip extends timeline further. At ₹3,000+ Cr capex (60% of total program), delay directly impacts medium-term returns.

New asset underutilization

Medium

MIBK/MIBC at 60%, acetophenone just ramping Q3. If market absorption slower, utilization stuck at 70–80% through FY28, leaving 20–30% capex unproductive. CDMO and specialty molecules still early-stage (kilo-lab to pilot phase).

Macro / geopolitical volatility reversal

Medium

Supply-chain normalization, freight normalization, or increased propylene / ammonia exports could reverse tailwinds. Phenol spreads would compress; AI raw material costs might fall, creating a double margin squeeze. Domestic demand resilient but not immune to global moderation.

How the market is reading this

The stock reacted day-1 +2.91% (delivery 39.1%), holding gains into day-3 (+2.99%). The initial pop suggests the market validated the reported profit and phenol strength. But this is deceiving: the stock is trading at ₹1,520.6, down 52% from its all-time high of ₹3,169 and below all key moving averages (SMA20 ₹1,540, SMA50 ₹1,603, SMA200 ₹1,620). RSI is 46.4 (neutral), not oversold. This disconnect—record profit but stock at a 52% drawdown—signals the market is skeptical that phenol cycle peak and AI margin deterioration will reverse.

Ownership flows are flat. FII holding steady at 6.25% (vs 6.19% prior quarter, +6bp); DII +29bp to 23.76%; promoter stable at 49.34%. No material institutional accumulation or trimming. The narrative: wait for AI margin recovery proof before re-rating.

The debate

What to watch next

  • 1 · Q3 FY27 AI EBIT margin recovery

    Management guided 'closer to Q1' (~11% from Q2's 6%). If Q3 comes in at 8–9%, recovery is phased and credibility on 14–15% FY28–29 target weakens. If 11%+, new asset ramp validates and re-rating risk emerges.

  • 2 · MIBK/MIBC utilization trajectory

    Currently 60%, targeting 100%+ by FY28. Track Q3 output and sales mix. If stuck at 70–80% by year-end, market absorption is slower than expected; risk to H2 FY27 guidance and FY28 EBIT accretion.

  • 3 · Polycarbonate FY31 entry—permit & pilot progress

    PDH plant (feedstock) and resin pilot qualification are gating items. Any permitting slip or pilot delay signals execution risk. Track investor presentation updates and management commentary on customer trial progress.

The number to track

AI EBIT in absolute terms (₹ Cr, not margin %). Q1 was ₹67 Cr, Q2 fell to ₹49 Cr. Q3 guidance path is 'between Q1 and Q2, closer to Q1' (so ₹55–62 Cr range). If Q3 delivers ₹60+ Cr, the recovery is credible. If ₹45–50 Cr, the ramp is stuck. That ₹15–20 Cr swing is the difference between a +15% 18-month EPS upside case and a −10% downside case. This number will determine whether polycarbonate thesis remains intact or needs recalibration.

Deepak Nitrite Q2 was a study in optics vs. substance. The headline—record ₹398 Cr PAT—is real, but it is a phenol story at commodity cycle peak. The future (polycarbonate, integrated platform, 14–15% AI EBIT) is credible long-term but not imminent. Management has earned credibility on execution (MIBK/MIBC on-time, propylene sourcing proactive, capex discipline), but the stock's 52% drawdown reflects justified caution on timing and AI ramp credibility. Wait for Q3 AI recovery proof before stepping in; if it lands, the narrative resets to 'platform transition validated' and re-rating risk emerges.

Informational and educational content only. Not investment advice.